Corporate GovernanceMay 19, 2026, 05:22 PM
Vaxart Files Proxy, Urges Support for Board Nominees
AI Summary
Vaxart, Inc. filed preliminary proxy materials and issued a letter to shareholders ahead of its Annual Meeting on July 16, 2026. The company highlighted its clinical and operational progress, strategic priorities, and commitment to long-term value creation, urging shareholders to support its six director nominees. Vaxart also addressed the nomination of three dissident director candidates, emphasizing the need for experienced leadership. The company reported approximately $61 million in cash resources for Q1 2026, providing a funded runway into Q2 2027, and provided updates on its COVID-19, Norovirus, and Influenza vaccine programs.
Key Highlights
- Vaxart scheduled its Annual Meeting for July 16, 2026.
- Company filed preliminary proxy materials with the SEC.
- Urges shareholders to support its six director nominees.
- Addresses nomination of three dissident director candidates.
- Q1 2026 cash resources were approximately $61 million.
- Company has a funded runway into the second quarter of 2027.
- Phase 2b COVID-19 trial sentinel cohort 12-month safety data expected Q2 2026.
- Primary efficacy/safety readout from main COVID-19 cohort anticipated early 2027.
Price Impact
More from VXRT